Literature DB >> 10360643

Rodent fibroblast model for studies of response of malignant cells to exogenous 5-aminolevulinic acid.

G Li1, M R Szewczuk, L Raptis, J G Johnson, G E Weagle, R H Pottier, J C Kennedy.   

Abstract

All nucleated mammalian cells synthesize protoporphyrin IX (PpIX) when exposed to exogenous 5-aminolevulinic acid (ALA). The response to exogenous ALA under standard conditions (the ALA phenotype) is characteristic for each cell type. Significantly more PpIX accumulates in malignant and premalignant cells than in the normal cells from which they were derived. A rodent fibroblast model was developed to study the mechanisms responsible for this phenomenon. Exogenous ALA induced the accumulation of substantial concentrations of PpIX in fibrosarcoma cells, and in immortalized fibroblasts transfected with the oncogene c-myc, IGF-1 receptor, IGF-1 and its receptor, v-fos, v-raf, v-Ki-ras, v-abl, or polyomavirus middle T antigen with G418 resistance selection. Much lower concentrations of PpIX accumulated in primary fibroblast cultures, in immortalized fibroblast cell lines, and in immortalized fibroblasts transfected with the G418-resistance gene only. The mechanisms responsible for the increased accumulation of ALA-induced PpIX by transformed cells (the malignant ALA phenotype) therefore appear to be closely linked to the mechanisms responsible for malignant transformation. Identification of the nature of that linkage may lead to new approaches to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360643      PMCID: PMC2362266          DOI: 10.1038/sj.bjc.6690409

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Regulation of cellular phenotype and expression of polyomavirus middle T antigen in rat fibroblasts.

Authors:  L Raptis; H Lamfrom; T L Benjamin
Journal:  Mol Cell Biol       Date:  1985-09       Impact factor: 4.272

2.  Conditional immortalization and/or transformation of rat cells carrying v-abl or EJras oncogene in the presence or absence of glucocorticoid hormone.

Authors:  T Yamashita; H Kato; K Fujinaga
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

3.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

4.  Effect of 5-aminolevulinic acid dose and estrogen on protoporphyrin IX concentrations in the rat uterus.

Authors:  B N Roy; D A Van Vugt; G E Weagle; R H Pottier; R L Reid
Journal:  J Soc Gynecol Investig       Date:  1997 Jan-Feb

5.  Phorbol ester and bryostatin differentially regulate the hydrolysis of phosphatidylethanolamine in Ha-ras- and raf-oncogene-transformed NIH 3T3 cells.

Authors:  Z Kiss; U R Rapp; G R Pettit; W B Anderson
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

6.  Detection of early stages of carcinogenesis in adenomas of murine lung by 5-aminolevulinic acid-induced protoporphyrin IX fluorescence.

Authors:  D L Campbell; E F Gudgin-Dickson; P G Forkert; R H Pottier; J C Kennedy
Journal:  Photochem Photobiol       Date:  1996-10       Impact factor: 3.421

7.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.

Authors:  J C Kennedy; R H Pottier; D C Pross
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

Review 8.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.

Authors:  J C Kennedy; R H Pottier
Journal:  J Photochem Photobiol B       Date:  1992-07-30       Impact factor: 6.252

Review 9.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results.

Authors:  J C Kennedy; S L Marcus; R H Pottier
Journal:  J Clin Laser Med Surg       Date:  1996-10

10.  Flow cytometric technique for quantitating cytotoxic response to photodynamic therapy.

Authors:  D L Campbell; M E Fisher; J G Johnson; F M Rossi; B G Campling; R H Pottier; J C Kennedy
Journal:  Photochem Photobiol       Date:  1996-01       Impact factor: 3.421

View more
  5 in total

1.  Mitochondrial Translocator Protein (TSPO) Function Is Not Essential for Heme Biosynthesis.

Authors:  Amy H Zhao; Lan N Tu; Chinatsu Mukai; Madhu P Sirivelu; Viju V Pillai; Kanako Morohaku; Roy Cohen; Vimal Selvaraj
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

2.  Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy.

Authors:  Vipin Shankar Chelakkot; Jayoti Som; Ema Yoshioka; Chantel P Rice; Suzette G Rutihinda; Kensuke Hirasawa
Journal:  Br J Cancer       Date:  2019-09-25       Impact factor: 7.640

3.  MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes.

Authors:  Vipin Shankar Chelakkot; Kaiwen Liu; Ema Yoshioka; Shaykat Saha; Danyang Xu; Maria Licursi; Ann Dorward; Kensuke Hirasawa
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

4.  Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response.

Authors:  Xue Yang; Pratheeba Palasuberniam; Kenneth A Myers; Chenguang Wang; Bin Chen
Journal:  Oncotarget       Date:  2016-09-06

5.  Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway.

Authors:  Ema Yoshioka; Vipin Shankar Chelakkot; Maria Licursi; Suzette G Rutihinda; Jayoti Som; Leena Derwish; Justin J King; Theerawat Pongnopparat; Karen Mearow; Mani Larijani; Ann M Dorward; Kensuke Hirasawa
Journal:  Theranostics       Date:  2018-03-08       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.